Revolution Medicines Inc: New oral doublet data at ESMO-GI soon could drive up to 40% more revs w new G12D Zoldon and remove chemo

研报英文原文证据摘录

Revolution Medicines Inc: New oral doublet data at ESMO-GI soon could drive up to 40% more revs w new G12D Zoldon and remove chemo

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any

materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a

complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the

Information. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided

by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances

may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following

purposes:

(i) valuation or accounting purposes;

(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or

(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of

defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information

for any of the above purposes or otherwise rely upon this document or any of the Information.